Background: One of the most prevalent malignant tumors in the world,
colorectal carcinoma (CRC) is still a major contributor to cancer-related
morbidity and mortality. Although the prognostic importance of CD133
and p63 in CRC has not yet been thoroughly established, recent data
indicates that they play crucial roles in the development and progression
of numerous human malignancies.
Aim: To evaluate CD133 and p63 immunohistochemical expression in
CRC, look into their relationship to clinicopathological characteristics
and patient survival, and examine the relationship between the two
markers.
Methods: Retrospective work was conducted on 50 established CRC.
Tissue sections were submitted to an immunohistochemical study for
CD133 and p63. Expression levels were correlated with
clinicopathological variables, including tumor grade, lymphovascular
invasion (LVI), distant metastasis, and tumor stage, as well as overall
patient survival.
Results: CD133 and p63 overexpression were significantly associated
with poor clinicopathological characteristics, including higher tumor
gradex, lymphovascular involvement, distant metastasis, and higher
stage. A strong association between marker expression and reduced
overall survival was identified. CD133 and p63 expression were shown to
be significantly positively correlated (ρ = 0.561, p < 0.001)
Conclusions: The findings suggest that CD133 and p63 are linked to
aggressive clinicopathological features and poorer survival results in
CRC. These markers may serve as potential prognostic biomarkers, and
their combined evaluation could help refine risk stratification and
therapeutic decision-making in CRC management. |
